论文部分内容阅读
用ＣＦＵ－ＧＭ半固体琼脂培养技术研究了抗人胸腺细胞球蛋白（ＡＴＧ）和抗ＣＤ３单克隆抗体（ＭｃＡｂ）对１８例再生障碍性贫血（ＡＡ）患者骨髓ＣＦＵ－ＧＭ体外生长的影响。结果表明，１．加入１６．７μｇ／ｍｌＡＴＧ或１：５０抗ＣＤ３ＭｃＡｂ，体外均可增加ＡＡ患者骨髓ＣＦＵ－ＧＭ的集落数（Ｐ＜０．０５），两者的作用无显著差异（Ｐ＞０．０５）。２．ＡＴＧ和抗ＣＤ３ＭｃＡｂ对ＡＡ患者干细胞缺乏型和免疫介导型的作用无显著差异（Ｐ＞０．０５）。用此项技术对ＡＡ患者作药敏试验，并加测外周血ＣＤ８＋、ＤＲ＋细胞比值，可作为选择免疫抑制疗法的参考。
The effects of anti-human thymocyte globulin (ATG) and anti-CD3 monoclonal antibody (McAb) on the growth of bone marrow CFU-GM in 18 patients with aplastic anemia (AA) were studied by CFU-GM semi-solid agar culture. The result shows that: 1. The addition of 16.7μg / ml ATG or 1:50 anti-CD3McAb could increase the number of CFU-GM colonies in AA patients (P <0.05) in vitro. There was no significant difference between the two groups (P> 0.05). 2. There was no significant difference between ATG and anti-CD3McAb on AA patients with SLE and immune-mediated (P> 0.05). With this technology in patients with AA susceptibility testing, and increase the ratio of peripheral blood CD8 +, DR + cells can be used as a reference for the selection of immunosuppressive therapy.